Outputs (8)

The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology (2020)
Journal Article
Yiu, Z., Mason, K., Smith, C., Griffiths, C., & Study Group, B. (2020). The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology. British Journal of Dermatology, 183(6), 981-983. https://doi.org/10.1111/bjd.19536

The coronavirus disease 2019 (COVID‐19) pandemic has led to unexpected challenges and adversity in the centenary year of the British Association of Dermatologists (BAD). However, through challenge comes opportunity. Two national organizations were bo... Read More about The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology.

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. (2020)
Journal Article
Iskandar, I., Warren, R., Lunt, M., Mason, K., Evans, I., McElhone, K., …Ashcroft, D. (2020). Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatology, 157(1), 66-73. https://doi.org/10.1001/jamadermatol.2020.4202

Importance: Treatments for psoriasis may be less effective in everyday practice than in clinical trials. Emulating a target trial using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) can provide t... Read More about Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register..

Factors associated with adverse COVID-19 outcomes in patients with psoriasis: insights from a global registry-based study (2020)
Journal Article
Mahil, S. K., Dand, N., Mason, K. J., Yiu, Z. Z. . N., Tsakok, T., Meynell, F., …study group, P. (2021). Factors associated with adverse COVID-19 outcomes in patients with psoriasis: insights from a global registry-based study. Journal of Allergy and Clinical Immunology, 147(1), 60-71. https://doi.org/10.1016/j.jaci.2020.10.007

BACKGROUND: The multi-morbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse COVID-19 outcomes but data are limited. OBJECTIVE: Characterize the course of COVID-19 in psoriasis and identify fa... Read More about Factors associated with adverse COVID-19 outcomes in patients with psoriasis: insights from a global registry-based study.

Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. (2020)
Journal Article
Mahil, S., Yiu, Z., Mason, K., Dand, N., Coker, B., Wall, D., …Smith, C. (in press). Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. British Journal of Dermatology, 183(2), 404 - 406. https://doi.org/10.1111/bjd.19161

'No abstract'

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (2020)
Journal Article
Yiu, Z., Mason, K., Hampton, P., Reynolds, N., Smith, C., Lunt, M., …Warren, R. (2020). Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology, 183(2), 294 - 302. https://doi.org/10.1111/bjd.18981

BACKGROUND: Real-world biologic drug survival is an important proxy measure for effectiveness. Predictors of drug survival may help patients with psoriasis choose between biologic therapies. OBJECTIVES: (i) To assess the relative drug survival of... Read More about Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)..

Factors associated with hospitalization due to COVID‐19 in patients with psoriasis: insights from a global registry (2020)
Presentation / Conference
Mahil, S., Dand, N., Mason, K., Yiu, Z., Tsakok, T., Meynell, F., …Smith, C. (2020, July). Factors associated with hospitalization due to COVID‐19 in patients with psoriasis: insights from a global registry. Paper presented at British Association of Dermatologists 100th Annual Meeting, Virtual

Psoriasis is a common immune‐mediated inflammatory skin disease with frequent multimorbidity, and immunosuppressants are the mainstay of treatment in moderate‐to‐severe disease. An understanding of the impact of COVID‐19 on individuals with psoriasis... Read More about Factors associated with hospitalization due to COVID‐19 in patients with psoriasis: insights from a global registry.

Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study (2020)
Journal Article
Loeff, F. C., Tsakok, T., Dijk, L., Hart, M. H., Duckworth, M., Baudry, D., …Warren, R. B. (2020). Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. Journal of Investigative Dermatology, 140(11), 2129-2137. https://doi.org/10.1016/j.jid.2020.03.957

Ustekinumab is an effective treatment for psoriasis, but response varies between patients. The formation of anti-drug antibodies (ADAs) may explain part of this variation by reducing the free ustekinumab level. Currently, published analyses of the cl... Read More about Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study.

Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review (2020)
Journal Article
Al-Janabi, A., Foulkes, A. C., Mason, K., Smith, C. H., Griffiths, C. E. M., & Warren, R. B. (2020). Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. Journal of the European Academy of Dermatology and Venereology, 34(7), 1440-1448. https://doi.org/10.1111/jdv.16246

The use of biologic therapies for the treatment of chronic plaque psoriasis has been linked to the development of atopic eczema, amongst other cutaneous adverse events. This can cause diagnostic confusion and create difficulty in the management of pa... Read More about Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.